News and Announcements
Punakaiki Fund Has Another Stab at Raising Money From Retail Investors
- Published November 22, 2016 2:47PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2nd November 2016, NBR By Fiona Rotherham
The Punakaiki Fund, which makes long-term investments in high-growth New Zealand companies, has launched fundraising offers at $19 per share in New Zealand and Australia with no set amount being targeted.
The New Zealand offer due to open on Nov. 9 is a public one open to anyone through a product disclosure statement (PDS) approved by the market regulator while the Australian one opens today and is to wholesale investors only.
Both offers close at the end of the month and are on the same terms apart from the New Zealand one having a minimum investment of $1,900 compared to a minimum $56,000 in Australia. It’s the first time the fund has attempted to raise money across the Tasman.
To view the full article, please click on the button below.
To receive the offer, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
